NIM
SMMT icon

NEOS Investment Management’s Summit Therapeutics SMMT Stock Holding History

NEOS Investment Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-97,217
Closed -$1.7M – 645
2025
Q4 		$1.7M Buy
97,217
+16,933
+21% +$319K 0.01% 493
2025
Q3 		$1.66M Sell
80,284
-26,659
-25% -$646K 0.01% 461
2025
Q2 		$2.28M Buy
106,943
+8,832
+9% +$201K 0.03% 347
2025
Q1 		$1.89M Buy
98,111
+71,470
+268% +$1.43M 0.04% 331
2024
Q4 		$475K Buy
+26,641
New +$516K 0.01% 512

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NEOS Investment Management's SMMT Position: Q1 2026 in Review

NEOS Investment Management sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 97,217 shares — an estimated $1.7M sold.

NEOS Investment Management first reported a position in SMMT in Q4 2024 and held it in 5 quarters. The position peaked at $2.28M in Q2 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • NEOS Investment Management reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • NEOS Investment Management sold 97,217 Summit Therapeutics shares in Q1 2026, an estimated $1.7M.
  • NEOS Investment Management first reported a position in Summit Therapeutics in Q4 2024 and held it in 5 quarters.
  • NEOS Investment Management's Summit Therapeutics position peaked at $2.28M in Q2 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.